This study involves taking a study drug called CUDC-907.  CUDC-907 is an oral drug that blocks certain
proteins in tumor cells; these proteins may be important in the growth of some
cancers. The overall goals of this study are to evaluate the side effects and
benefits of CUDC-907 in patients with relapsed or treatment refractory solid
tumor, brain tumor, or lymphoma, and to determine the best dose of CUDC-907 for
children and adolescents.  This study
will also look at the levels of CUDC-907 in the blood over time after a dose.